LifeArc boosts investment in Cambridge University spin-out PolyProx Therapeutics to advance new class of cancer medicines
Published on 2 Mar 2020
Plasticell obtains further funding to wrap up pre-clinical development of expanded cord blood stem cell product.
Published on 25 Feb 2020
Stevenage Bioscience Catalyst Life Science Opportunity Zone
Published on 20 Feb 2020
Freeline presents data on its AAV-based gene therapies for Fabry Disease and Gaucher Disease at the 16th annual WORLDSymposium™
Published on 12 Feb 2020
Freeline appoints Theresa Heggie as Chief Executive
Published on 4 Feb 2020
LifeArc and Action Medical Research launch funding call for research into rare diseases in children
Published on 31 Jan 2020
New Cell and Gene Therapy Catapult CEO brings continuity and ambition for further impact
Published on 29 Jan 2020
Supporting progress of cell and gene therapy industrialisation with new aseptic manufacturing course
Published on 20 Jan 2020
UK accounts for over 12% of global cell and gene therapy clinical trials
Published on 15 Jan 2020

Peptinnovate announces change of name to Immune Regulation, strengthening of the Board and successful fundraise

Read the article
The appointment of these three experienced industry executives will bring valuable insight and resource to our Board and executive team. With their skills in immunology, clinical therapeutic development and strategy we have the expertise to advance our clinical programmes and look forward to the next stage of our progress.
Prof. Clive Page
Chairman of Immune Regulation
KaNDy Therapeutics Announces Positive Phase 2b Data in Post-Menopausal Women with its Lead Non-Hormonal Product NT-814
Published on 13 Jan 2020
Syncona makes a further $80 million commitment to Freeline
Published on 19 Dec 2019
ReViral Appoints Lawrence Blatt and Richard N. Kender to its Board of Directors
Published on 27 Nov 2019
Investment in UK cell and gene therapy manufacturing set to continue
Published on 27 Nov 2019
Accelerated demand for specialist skills in the UK cell and gene therapy industry
Published on 27 Nov 2019
£1.2m investment to reinforce Stevenage Campus as world class cell and gene therapy hub
Published on 19 Nov 2019
Phase 2a Study Published in Antimicrobial Agents and Chemotherapy Shows Potential of Sisunatovir (RV521) to Combat Respiratory Syncytial Virus Infection
Published on 18 Nov 2019
New report indicates more than 10% of the UK’s top female BioBusiness talent is based at Stevenage Bioscience Catalyst.
Published on 5 Nov 2019
ReViral Announces Appointment of Alan Musso as Chief Financial Officer
Published on 21 Oct 2019
Patients with ultra-rare bone marrow disease set to benefit from £1.15m grant from LifeArc and The Aplastic Anaemia Trust
Published on 21 Oct 2019
TCR² Therapeutics Appoints Industry Veteran Angela Justice, Ph.D., As Chief People Officer
Published on 9 Oct 2019
Business and Industry Minister announces Stevenage Bioscience Catalyst as one of six new Life Science Opportunity Zones in UK
Published on 7 Oct 2019

Copyright © 2020 Stevenage Bioscience Catalyst

Designed and built by Onespacemedia

We use cookies to improve our site experience. Press accept to agree to our Cookie Policy. If you decline, your information won’t be tracked when you visit this website. A single cookie will be used in your browser to remember your preference not to be tracked.